Comment on: Alopecia in Multiple Sclerosis Patients Treated with Disease Modifying Therapies

With great interest we read the publication by Porwal MH et al. With 117 registered cases, a high number of unreported cases can be postulated. If younger patients with multiple sclerosis (PwMS) tend to be affected more frequently, preventive oral vitamin D (VitD) supplementation should be discussed. This adjuvant VitD administration during the entire 48-month therapy with alemtuzumab (ALEM) has a double benefit. There is increasing evidence that the serum level of VitD influences the severity and duration of alopecia areata (AA). VitD deficiency plays a major role in pathogenesis and therapy. Several studies revealed that serum VitD levels significantly and inversely correlate with the duration and severity of AA. Patient affected by various autoimmune diseases showed low serum levels of VitD (25(OH)D). VitD plays a role in the pathogenesis of AA. Lin et al are currently showing the connections between vitD and AA. VitD plays a role in the pathogenesis of AArelated